PortfoliosLab logoPortfoliosLab logo
PRAA vs. BIO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

PRAA vs. BIO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in PRA Group, Inc. (PRAA) and Bio-Rad Laboratories, Inc. (BIO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, PRAA achieves a 4.52% return, which is significantly higher than BIO's -2.27% return. Over the past 10 years, PRAA has underperformed BIO with an annualized return of -3.65%, while BIO has yielded a comparatively higher 7.41% annualized return.


PRAA

1D
1.20%
1M
19.14%
6M
5.36%
YTD
4.52%
1Y
17.10%
3Y*
-5.43%
5Y*
-13.23%
10Y*
-3.65%

BIO

1D
-0.39%
1M
3.56%
6M
-8.56%
YTD
-2.27%
1Y
15.23%
3Y*
-9.17%
5Y*
-15.20%
10Y*
7.41%
*Multi-year figures are annualized to reflect compound growth (CAGR)

PRAA vs. BIO - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
PRAA
PRA Group, Inc.
4.52%-15.32%-20.27%-22.44%-32.72%26.60%9.26%48.95%-26.60%-15.09%
BIO
Bio-Rad Laboratories, Inc.
-2.27%-7.77%1.74%-23.21%-44.35%29.61%57.54%59.34%-2.70%30.94%

Correlation

The correlation between PRAA and BIO is 0.31, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.31

Correlation (3Y)
Calculated over the trailing 3-year period

0.36

Correlation (5Y)
Calculated over the trailing 5-year period

0.30

Correlation (10Y)
Calculated over the trailing 10-year period

0.25

Correlation (All Time)
Calculated using the full available price history since Nov 8, 2002

0.31

The correlation between PRAA and BIO shifts across timeframes, from 0.25 (10 years) to 0.36 (3 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

PRAA:

$705.23M

BIO:

$8.01B

EPS

PRAA:

-$7.21

BIO:

$6.26

PS Ratio

PRAA:

0.56

BIO:

3.08

PB Ratio

PRAA:

0.71

BIO:

1.17

Total Revenue (TTM)

PRAA:

$1.28B

BIO:

$2.59B

Gross Profit (TTM)

PRAA:

$1.31B

BIO:

$1.34B

EBITDA (TTM)

PRAA:

-$47.90M

BIO:

$746.20M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

PRAA vs. BIO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PRAA
PRAA Risk / Return Rank: 5454
Overall Rank
PRAA Sharpe Ratio Rank: 5454
Sharpe Ratio Rank
PRAA Sortino Ratio Rank: 5454
Sortino Ratio Rank
PRAA Omega Ratio Rank: 5454
Omega Ratio Rank
PRAA Calmar Ratio Rank: 5454
Calmar Ratio Rank
PRAA Martin Ratio Rank: 5555
Martin Ratio Rank

BIO
BIO Risk / Return Rank: 5757
Overall Rank
BIO Sharpe Ratio Rank: 5858
Sharpe Ratio Rank
BIO Sortino Ratio Rank: 5656
Sortino Ratio Rank
BIO Omega Ratio Rank: 5555
Omega Ratio Rank
BIO Calmar Ratio Rank: 5757
Calmar Ratio Rank
BIO Martin Ratio Rank: 5757
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PRAA vs. BIO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for PRA Group, Inc. (PRAA) and Bio-Rad Laboratories, Inc. (BIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


PRAABIODifference
Sharpe ratioReturn per unit of total volatility

-0.09

Sortino ratioReturn per unit of downside risk

-0.07

Omega ratioGain probability vs. loss probability

1.10

1.11

0.00

Calmar ratioReturn relative to maximum drawdown

0.33

0.49

-0.16

Martin ratioReturn relative to average drawdown

0.80

1.09

-0.29

PRAA vs. BIO - Sharpe Ratio Comparison

The current PRAA Sharpe Ratio is 0.24, which is comparable to the BIO Sharpe Ratio of 0.33. The chart below compares the historical Sharpe Ratios of PRAA and BIO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

PRAA vs. BIO - Drawdown Comparison

The maximum PRAA drawdown since its inception was -83.83%, roughly equal to the maximum BIO drawdown of -83.64%. Use the drawdown chart below to compare losses from any high point for PRAA and BIO.


Loading charts...

Drawdown Indicators


PRAABIODifference

Max Drawdown

Largest peak-to-trough decline

-83.83%

-83.64%

-0.19%

Max Drawdown (1Y)

Largest decline over 1 year

-42.34%

-28.86%

-13.48%

Max Drawdown (3Y)

Largest decline over 3 years

-62.79%

-48.76%

-14.03%

Max Drawdown (5Y)

Largest decline over 5 years

-79.35%

-73.77%

-5.58%

Max Drawdown (10Y)

Largest decline over 10 years

-79.35%

-73.77%

-5.58%

Current Drawdown

Current decline from peak

-71.32%

-64.14%

-7.18%

Average Drawdown

Average peak-to-trough decline

-32.42%

-27.81%

-4.61%

Ulcer Index

Depth and duration of drawdowns from previous peaks

17.39%

12.83%

+4.56%

Volatility

PRAA vs. BIO - Volatility Comparison

PRA Group, Inc. (PRAA) has a higher volatility of 15.73% compared to Bio-Rad Laboratories, Inc. (BIO) at 11.24%. This indicates that PRAA's price experiences larger fluctuations and is considered to be riskier than BIO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


PRAABIODifference

Volatility (1M)

Calculated over the trailing 1-month period

15.73%

11.24%

+4.49%

Volatility (6M)

Calculated over the trailing 6-month period

49.90%

29.92%

+19.98%

Volatility (1Y)

Calculated over the trailing 1-year period

58.48%

42.20%

+16.28%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

50.09%

37.58%

+12.51%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

46.67%

34.19%

+12.48%

Dividends

PRAA vs. BIO - Dividend Comparison

Neither PRAA nor BIO has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

PRAA vs. BIO - Financials Comparison

This section allows you to compare key financial metrics between PRA Group, Inc. and Bio-Rad Laboratories, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


200.00M300.00M400.00M500.00M600.00M700.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026
314.53M
592.10M
(PRAA) Total Revenue
(BIO) Total Revenue
Values in USD except per share items

PRAA vs. BIO - Profitability Comparison

The chart below illustrates the profitability comparison between PRA Group, Inc. and Bio-Rad Laboratories, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

30.0%40.0%50.0%60.0%70.0%80.0%JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober2026
77.5%
52.3%
Portfolio components
PRAA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, PRA Group, Inc. reported a gross profit of 243.80M and revenue of 314.53M. Therefore, the gross margin over that period was 77.5%.

BIO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jul 2026, Bio-Rad Laboratories, Inc. reported a gross profit of 309.40M and revenue of 592.10M. Therefore, the gross margin over that period was 52.3%.

PRAA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, PRA Group, Inc. reported an operating income of 103.25M and revenue of 314.53M, resulting in an operating margin of 32.8%.

BIO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jul 2026, Bio-Rad Laboratories, Inc. reported an operating income of 34.10M and revenue of 592.10M, resulting in an operating margin of 5.8%.

PRAA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, PRA Group, Inc. reported a net income of 28.21M and revenue of 314.53M, resulting in a net margin of 9.0%.

BIO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jul 2026, Bio-Rad Laboratories, Inc. reported a net income of -527.10M and revenue of 592.10M, resulting in a net margin of -89.0%.


Frequently Asked Questions


PRAA and BIO have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

PRAA has higher volatility (15.73%) compared to BIO (11.24%). In terms of maximum drawdown, PRAA dropped -83.83% vs BIO's -83.64%.

BIO currently has the higher Sharpe Ratio (0.33 vs 0.24), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for PRAA and BIO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer